BRAF directed therapy, dabrafenib plus trametinib is now approved for treatmentlung cancer patients where BRAF mutations are noted in about 2–4% of patients (60), however, their utility in lung cancer with brain metastases is yet to be evaluated. The gene discussed is BRAF; the disease is lung carcinoma.